Merck and Moderna Cancer Vaccine Shows Promise as China Faces Expedited Trial Backlash

China's expedited trials have taken another toll, with a third reported death in recent weeks. The development highlights concerns about the country's fast-tracking of medical research and treatments.

On a more positive note, Merck and Moderna announced topline results for their personalized cancer vaccine, which showed promising efficacy rates.

The news comes as China grapples with its own work ethic and pace of medical innovation. Some experts have raised concerns that the country's emphasis on speed over safety may be having unintended consequences.